Cardiovascular Implications of microRNAs in Coronavirus Disease 2019

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to be a global challenge due to resulting morbidity and mortality. Cardiovascular (CV) involvement is a crucial complication in coronavirus disease 2019 (COVID-19), and no strategies are available to prevent or speci...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pharmacology and experimental therapeutics 2023-01, Vol.384 (1), p.102-108
Main Authors: Izzo, Carmine, Visco, Valeria, Gambardella, Jessica, Ferruzzi, Germano Junior, Rispoli, Antonella, Rusciano, Maria Rosaria, Toni, Anna Laura, Virtuoso, Nicola, Carrizzo, Albino, Di Pietro, Paola, Iaccarino, Guido, Vecchione, Carmine, Ciccarelli, Michele
Format: Article
Language:English
Subjects:
Biomarkers - metabolism
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - virology
COVID-19 - complications
Humans
MicroRNAs - metabolism
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to be a global challenge due to resulting morbidity and mortality. Cardiovascular (CV) involvement is a crucial complication in coronavirus disease 2019 (COVID-19), and no strategies are available to prevent or specifically address CV events in COVID-19 patients. The identification of molecular partners contributing to CV manifestations in COVID-19 patients is crucial for providing early biomarkers, prognostic predictors, and new therapeutic targets. The current report will focus on the role of microRNAs (miRNAs) in CV complications associated with COVID-19. Indeed, miRNAs have been proposed as valuable biomarkers and predictors of both cardiac and vascular damage occurring in SARS-CoV-2 infection. It is essential to identify the molecular mediators of coronavirus disease 2019 (COVID-19) cardiovascular (CV) complications. This report focused on the role of microRNAs in CV complications associated with COVID-19, discussing their potential use as biomarkers, prognostic predictors, and therapeutic targets.
ISSN:0022-3565
1521-0103
DOI:10.1124/jpet.122.001210